^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MRD4 negative

    i
    Other names: MRD4, Mental Retardation, Autosomal Dominant 4
    Entrez ID:
    112441440
    2years
    First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL) (ASH 2022)
    Early data shows that NVG-111 is generally well tolerated with a predictable and manageable safety profile. Promising evidence of efficacy was observed which appears to be durable in two subjects with MRD4 negative CR. Dose escalation is ongoing in combination or as monotherapy to determine the MTD/RP2D.
    Clinical • P1 data • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    MRD4 negative
    |
    Imbruvica (ibrutinib) • NVG-111